Combined Use of BCG and Interferon Alpha in Bladder Cancer
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To compare the toxicity and efficacy of the combination of BCG and interferon alpha to
standard dose and low dose BCG alone in high risk superficial bladder cancer
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National University Hospital, Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore